Posted by Michael Wonder on 12 Jan 2024
European Commission approves Krazati (adagrasib) as a targeted treatment option for patients with advanced non-small-cell lung cancer with a KRAS G12C mutation
10 January 2024 - Mirati Therapeutics today announced that the European Commission granted conditional marketing authorisation for Krazati (adagrasib) as a targeted treatment option for adult patients with KRASG12C mutated advanced non-small-cell lung cancer and disease progression after at least one prior systemic therapy.
Krazati has demonstrated a positive benefit-risk profile based on the Phase 2 registration enabling cohort of the KRYSTAL-1 study, evaluating Krazati 600 mg administered orally twice daily in 116 patients with KRAS G12C mutated advanced non-small-cell lung cancer who previously received treatment with a platinum-based regimen and an immune checkpoint inhibitor.
